Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt
By David Sachs
Grifols shares jumped Friday after the pharmaceutical company said it will sell a sizable stake in a Chinese medicine developer for $1.76 billion in order to pay down debt.
The Barcelona-based group said Friday that it will sell a roughly 20% stake in Shanghai RAAS Blood Products to Haier Group, a Chinese appliance company with a biomedical unit, for 12.5 billion Chinese yuan. Grifols will use the proceeds to pay off debt, it said.
At 1417 GMT, shares in Grifols were up 9.4% to EUR15.57, having risen as high as EUR15.92.
Grifols will still hold an approximate stake of 6.6% in Shanghai RAAS and a seat on its board of directors following the transaction, which is subject to standard regulatory closing conditions, the company said.
"Grifols and Haier envision broad cooperation to contribute to China's growing and developing healthcare system," Grifols said.
Shanghai RAAS's 45% stake in Grifols Diagnostic Solutions and 40% voting rights in the company will remain the same.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 29, 2023 09:44 ET (14:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom